ACT Obtains Exclusive License To Dual Mechanism Anti-Cancer Therapeutic From The University Of Louisville's Brown Cancer Cent

Advanced Cancer Therapeutics (ACT), a for-profit private company dedicated to bringing new anti-cancer therapies to market, announced that it has signed an exclusive license to develop and market 3PO and its related compounds, discovered by scientists at the University of Louisville's James Graham Brown Cancer Center. Brown Cancer Center researchers Dr. Jason Chesney and Dr.